Abstract:Elder patients with non-small cell lung cancer (NSCLC) have been habitually underrepresented in clinical trails. Retrospective analysis have shown similar therapeutic outcome of platinum-based combined chemotherapy for fit elderly, albeit more toxicity compared with younger coun-terparts. Gefitinib, an oral EGFR-TKI was generally well tolerated with clinically meaningful anti-tumor activity in previously treated patients as well as chemo-naïve patients. The aim of the study was to retrospectively evaluate the toxicity, efficacy and survival of gefitinib versus platinum-based combined chemotherapy as first-line treatment for a series of Chinese patients aged 70 and over with advanced NSCLC. from January 2002 to December 2005, 38 patients received chemotherapy (17 of Novelbine, 8 of Gemcitabine, 7 of taxol and 7 of taxotere, all of which combined with cisplatin or carboplatin) and 17 patients received gefitinib 250mg once daily as first line treatment. Of the 38 patients who received chemotherapy, the median age was 73.3 years old (70-80) with 68.4% male, 73.7% adenocarcinoma and 78.9% patients were in stage 4. The PS of all patients was 0-1. Of the 17 patients who received gefitinib, the median age was 76.9 years old (70-85) with 58.8% male, 64.7% adenocarcinoma and 82.4% patients were in stage 4. The PS of 6 patients was over 2. The most frequently reported adverse events for chemotherapy group were neutropenia (92.1%) and thrombocytopenia(73.7%). Grade 3/4 neutropenia was 21.1% and four patients had nertropenia febril. Grade 3/4 thrombocytopenia was 10.5% and 2 patients need blood transfusion. Other grade 3/4 adverse effects included 3 cases of vomiting and one case of cardiac arrhythmia. 4 patients withdrew the chemotherapy due to side effects. The most frequently reported adverse events for gefitinib group were skin disorders (70.6%) and diarrhea (35.3%). The majority of these events were mild with grade 1 to grade 2. One patient was hospitalization due to grade 3 diarrhea and recovered without drug administration disruption. Other adverse events included 2 cases of nausea, 1 case of oral ulcer and 1 case of elevation in hepatic enzymes. No patient withdrew due to adverse effect. The par-tial response and disease control rate were 21.1% and 78.9% for chemotherapy group versus 17.6% and 68.8% for gefitinib group. The median progress free survival and overall survival time were 4.93 ± 0.747 months (95% CI: 3.465, 7.395) and 13.882 ± 0.718 months (95% CI: 12.892, 20.708) for chemotherapy group versus 6.4 ± 1.852 months (95%CI: 2.770, 10.030) and 15.882 ± 2.029 months (95%CI: 13.654, 20.505). The one-year survival was 52.6% in chemotherapy group versus 47.1% in gefitinib group. There is no statisti-cal significance between the two groups for efficacy, progress free survival time and overall survival time. Platinum-based combined chemotherapy was well tolerated and provides significant anti-tumor activity in elder patients. Gefitinib as first-line treatment provides similar clinical benefit with less toxicity for the elder NSCLC patients.

Meta-Analysis of First-Line Pemetrexed Plus Platinum Treatment in Compared to Other Platinum-Based Doublet Regimens in Elderly East Asian Patients with Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Efficacy of Pemetrexed Plus Platinum Doublet Chemotherapy As First-Line Treatment for Advanced Nonsquamous Non-Small-cell-lung Cancer: a Systematic Review and Meta-Analysis.

Pemetrexed Plus Platinum or Gemcitabine Plus Platinum for Advanced Non-Small Cell Lung Cancer: Final Survival Analysis from A Multicentre Randomized Phase Ii Trial in the East Asia Region and A Meta-Analysis

Pemetrexed and Platinum As First-Line Chemotherapy for Advanced Lung Adenocarcinoma:An Observation of Recent Therapeutic Effects and a Safety Profile

[A Randomized, Controlled, Multicenter Clinical Trial Comparing Pemetrexed/cisplatin and Gemcitabine/cisplatin As First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer].

Efficacy and Safety of First-Line Pemetrexed Plus Carboplatin Followed by Single-Agent Pemetrexed Maintenance in Elderly Chinese Patients with Non-Squamous Non-Small-cell Lung Cancer

Efficacy of Third‐generation Chemotherapeutic Agents Combined with Cisplatin or Carboplatin in 3100 Chinese Patients with Advanced Non‐small‐cell Lung Cancer

P2-325: Chemotherapy in elderly (Over 75 years old)lung cancer patients: a retrospective analysis

Chemotherapy in elderly (Over 75 years old)lung cancer patients: a retrospective analysis: P2-325

Efficacy and Safety of Pemetrexed Maintenance Therapy Versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell Lung Cancer: an Exploratory Subgroup Analysis of a Global, Randomized, Phase 3 Clinical Trial

Clinical Observation and Prognostic Analysis of Pemetrexed Plus Platinum As First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer.

Pemetrexed Monotherapy Versus Pemetrexed Plus Platinum Combination As Second-Line Treatment for Advanced Non-Small Cell Lung Cancer

P3-163: Gefitinib versus chemotherapy as first-line treatment in elder patients with advanced non-small-cell lung cancer

Pemetrexed As the First-Line Therapy for Chinese Patients with Advanced Non-Squamous Non-Small-cell Lung Cancer.

Study on the treatment of advanced lung adenocarcinoma in the elderly with pemetrexed combined with platinum drugs

Efficacy and safety of chemotherapy regimens for first-line treatment of advanced esophageal squamous cell carcinoma in Asia: a systematic review

Clinical Effectiveness and Clinical Toxicity Associated with Platinum-Based Doublets in the First-Line Setting for Advanced Non-Squamous Non-Small Cell Lung Cancer in Chinese Patients: a Retrospective Cohort Study.

An East Asian subgroup analysis of PROCLAIM, a phase III trial of pemetrexed and cisplatin or etoposide and cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small cell lung cancer.

Efficacy and Safety of First-line Pembrolizumab Plus Platinum and Pemetrexed in Elderly Patients with Non-squamous Non-small-cell Lung Cancer

Efficacy and safety of pemetrexed or gemcitabine combined with carboplatin as the first-line therapy in elderly patients with advanced non-small cell lung cancer]

Outcomes of Pemetrexed-based chemotherapies in HER2 -mutant lung cancers